{"entity":{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","aka":["Limited-stage Hodgkin lymphoma","Stage I to II classical Hodgkin lymphoma","Early favourable and early unfavourable Hodgkin lymphoma","Localised Hodgkin lymphoma"],"tldr":"Early-stage classical Hodgkin lymphoma is Hodgkin lymphoma confined to one or two lymph node regions on one side of the diaphragm, one of the most curable cancers, with most patients cured by a short course of ABVD chemotherapy with or without radiotherapy to the involved nodes. Because patients are young, trials now use PET scans after two cycles to give as little treatment as safely possible.","summary":"Classical Hodgkin lymphoma is a B-cell lymphoma in which the malignant Hodgkin and Reed-Sternberg cells, CD30 and CD15 positive and usually CD20 negative, are outnumbered by a reactive inflammatory background; nodular sclerosis is the commonest subtype in young adults, and PD-L1 amplification at 9p24.1 is near universal. Stage I and II disease is divided into favourable and unfavourable groups by the presence of bulky disease, raised erythrocyte sedimentation rate, B symptoms, three or more nodal sites or extranodal extension, definitions that differ slightly between the German Hodgkin Study Group (GHSG) and the EORTC. Radiotherapy alone cured most patients with early disease from the 1960s, but the second cancers and heart disease it caused decades later drove the shift to combined chemotherapy with smaller radiation fields and lower doses.\n\nGHSG HD10 (New England Journal of Medicine 2010) showed that two cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) with 20 Gy of involved-field radiotherapy was enough for favourable disease, and HD11 and HD14 defined four cycles of chemotherapy (or two escalated BEACOPP plus two ABVD) with 30 Gy for unfavourable disease. Interim PET then became the tool for de-escalation: the RAPID trial (New England Journal of Medicine 2015) and EORTC H10 showed that omitting radiotherapy in patients who were PET-negative after two or three ABVD cycles costs a few percentage points of progression-free survival without a survival difference, and HD16 and HD17 refined which PET-negative patients can safely skip radiotherapy, so today many patients receive chemotherapy alone and the rest involved-site radiotherapy with modern conformal or proton techniques that spare the heart and breasts. Brentuximab vedotin and PD-1 antibodies, established in advanced disease, are moving into early-stage trials: the Children's Oncology Group AHOD2131 trial compares brentuximab vedotin with nivolumab against standard chemotherapy in early-stage high-risk disease in patients from age 5 to 60, and the GHSG HD21 and NIVAHL programmes test PD-1 antibodies with reduced chemotherapy. Fertility preservation, cardiac protection and lifelong survivorship care, including breast screening for women irradiated young, are part of standard management.","asOf":"2026-09-18","wikipedia":"https://en.wikipedia.org/wiki/Hodgkin_lymphoma","links":[{"label":"GHSG HD10 (NEJM 2010)","url":"https://doi.org/10.1056/NEJMoa1000067"},{"label":"RAPID (NEJM 2015)","url":"https://doi.org/10.1056/NEJMoa1408648"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Hodgkin_lymphoma"},{"label":"Lymphoma Action: helpline services","url":"https://lymphoma-action.org.uk/information-and-support/support-you/helpline-services"},{"label":"Lymphoma Action: questions to ask your medical team about lymphoma","url":"https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/questions-ask-your-medical-team-about-lymphoma"},{"label":"Lymphoma Action: follow-up after lymphoma treatment","url":"https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/follow-after-lymphoma-treatment"},{"label":"Lymphoma Action: infections, risk and prevention","url":"https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention"},{"label":"Lymphoma Action: neutropenia (low neutrophils)","url":"https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils"},{"label":"Lymphoma Action: cancer-related fatigue","url":"https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/cancer-related-fatigue"},{"label":"Lymphoma Action: lymphoma, work and you","url":"https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/day-day-living/lymphoma-work-and-you"},{"label":"Maggie's: support and information","url":"https://www.maggies.org/support-and-information/"},{"label":"Lymphoma Action: classical Hodgkin lymphoma","url":"https://lymphoma-action.org.uk/information-and-support/types-lymphoma/hodgkin-lymphoma/classical-hodgkin-lymphoma"},{"label":"Lymphoma Action: late effects of lymphoma treatment","url":"https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/late-effects-lymphoma-treatment"},{"label":"GOV.UK: protocols for surveillance of women at higher risk of developing breast cancer, NHS Breast Screening Programme","url":"https://www.gov.uk/government/publications/breast-screening-higher-risk-women-surveillance-protocols/protocols-for-surveillance-of-women-at-higher-risk-of-developing-breast-cancer"},{"label":"Lymphoma Action: annual breast screening missed following radiotherapy for Hodgkin lymphoma","url":"https://lymphoma-action.org.uk/news/annual-breast-screening-missed-following-radiotherapy-hodgkin-lymphoma"},{"label":"Schaapveld et al., second cancer risk up to 40 years after treatment for Hodgkin's lymphoma, New England Journal of Medicine 2015 (3,905 Dutch survivors)","url":"https://doi.org/10.1056/NEJMoa1505949"}],"tags":["subtype-page","haematologic"],"related":["advanced-stage-classical-hodgkin-lymphoma","relapsed-refractory-hodgkin-lymphoma","nodular-lymphocyte-predominant-hodgkin-lymphoma","hodgkin-lymphoma","primary-mediastinal-b-cell-lymphoma","lymphoma-roadmap","lymphoma-ev-radiotherapy-free-early-hodgkin"],"cancers":[],"sections":[],"technologies":["fdg-pet","pet-adapted-therapy","imrt-igrt","proton-therapy","cardio-oncology","fertility-preservation","ctdna-lymphoma-monitoring","mammography","palliative-care","psycho-oncology","peer-support-groups","survivorship-care-plan","financial-navigation","cbt-fatigue-distress","exercise-during-chemotherapy","multidisciplinary-tumour-board","oncology-nutrition","prehabilitation"],"targets":["cd30","pd1"],"drugs":["doxorubicin","vinblastine","dacarbazine","brentuximab-vedotin","nivolumab","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":["deauville-score","reed-sternberg-cell","lugano-classification","abvd-beacopp","late-effects","lymphoma-tx-radiotherapy","lymphoma-tx-hodgkin-late-effects","lymphoma-tx-fertility-preservation","lymphoma-tx-transplant-role","lymphoma-tx-uk-versus-us","lymphoma-tx-uk-access","lymphoma-tx-regimen-alphabet","cancer-related-fatigue","febrile-neutropenia","neutropenia","financial-toxicity","central-venous-access","hypogammaglobulinaemia","performance-status","quality-of-life","lymphoma-decision-fertility-timing","lymphoma-decision-trial","lymphoma-living-hodgkin-survivorship-screening","lymphoma-living-fatigue","secondary-malignancy","cardiotoxicity"],"trials":["ahod2131","nct03407144","hd10","hd16","eortc-h10","radar-hodgkin"],"people":[],"bottlenecks":[],"keyPapers":["paper-echelon-1-brentuximab-avd-nejm-2018","paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010","paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015"],"journals":[],"dependsOn":[],"notes":["Early-stage Hodgkin lymphoma, and the screening that follows a cure: This is orientation from public patient pages, guidelines and the trials themselves, not advice for your case: your own team's instructions and the 24-hour number they gave you come first, and no figure here is a prediction about you. The decision records, the question sets, the first 60 days checklist and the red cards on this page were written from the NHS, Lymphoma Action, Macmillan and Cancer Research UK patient pages, from NICE NG52, NG47, CG151 and NG234, from the NHS Breast Screening Programme protocols and the Green Book, and from the trial reports named beside each figure, all read on 1 October 2026."],"group":"haematologic","burden":"About half of classical Hodgkin lymphoma, typically in young adults with painless neck or mediastinal nodes; cure rates exceed nine in ten, so the modern problem is avoiding late harm from treatment.","subtypes":["Early favourable classical Hodgkin lymphoma (stage I to II without risk factors; two ABVD and 20 Gy or PET-guided chemotherapy alone)","Early unfavourable classical Hodgkin lymphoma (bulk, raised ESR, three or more sites or extranodal extension)","Nodular sclerosis classical Hodgkin lymphoma (commonest in young adults, mediastinal)","Mixed cellularity classical Hodgkin lymphoma (EBV-positive, children and older adults)","Lymphocyte-rich classical Hodgkin lymphoma","Paediatric and adolescent early-stage classical Hodgkin lymphoma (Children's Oncology Group risk groups)"],"biomarkers":["Interim FDG-PET after two cycles (Deauville score; guides omission of radiotherapy)","CD30 and CD15 on Hodgkin and Reed-Sternberg cells; CD20 usually negative","Bulky disease, erythrocyte sedimentation rate, B symptoms and number of sites (GHSG and EORTC risk factors)","EBV status (EBER) in mixed cellularity disease","Baseline metabolic tumour volume (prognostic, research)","Circulating tumour DNA (research; PhasED-seq)"],"standardOfCare":[{"setting":"Staging","approach":"FDG-PET/CT with Lugano staging; bone marrow biopsy no longer needed when PET is used; fertility counselling and cardiac baseline.","refs":["fdg-pet","lugano-classification","fertility-preservation","cardio-oncology"],"guideline":{"version":"NCCN Guidelines: Hodgkin Lymphoma","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439"}},{"setting":"Early favourable disease","approach":"Two cycles of ABVD with 20 Gy involved-site radiotherapy (HD10); or PET-adapted chemotherapy alone (three ABVD if PET-negative after two, RAPID and H10) accepting a small increase in relapse.","refs":["doxorubicin","vinblastine","dacarbazine","abvd-beacopp","imrt-igrt","pet-adapted-therapy","deauville-score"],"guideline":{"version":"NCCN Guidelines: Hodgkin Lymphoma","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439"}},{"setting":"Early unfavourable disease","approach":"Four cycles of ABVD (or two escalated BEACOPP plus two ABVD) with 30 Gy involved-site radiotherapy; radiotherapy omitted in PET-negative patients after HD17.","refs":["doxorubicin","vinblastine","dacarbazine","abvd-beacopp","imrt-igrt","pet-adapted-therapy"],"guideline":{"version":"NCCN Guidelines: Hodgkin Lymphoma","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439"}},{"setting":"Children and adolescents","approach":"Response-adapted Children's Oncology Group regimens with radiotherapy for slow responders; AHOD2131 tests brentuximab vedotin with nivolumab.","refs":["ahod2131","brentuximab-vedotin","nivolumab","childrens-oncology-group"],"guideline":{"version":"NCCN Guidelines: Hodgkin Lymphoma","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439"}},{"setting":"Survivorship","approach":"Cardiac surveillance, breast screening from eight years after chest radiotherapy in women, thyroid checks and second-cancer awareness for life.","refs":["cardio-oncology","mammography","late-effects"],"guideline":{"version":"NCCN Guidelines: Hodgkin Lymphoma","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439"}},{"setting":"Early favourable Hodgkin lymphoma: two cycles of ABVD and 20 Gy, and the argument about leaving the radiotherapy out","approach":"GHSG HD10 established the smallest combined-modality treatment that works: two cycles of ABVD followed by 20 Gy involved-field radiotherapy gave five-year freedom from treatment failure of about 93 per cent and overall survival of about 97 per cent, with no advantage from four cycles or from 30 Gy, and fewer acute adverse events at the lower intensity. Four visits of chemotherapy and a fortnight of radiotherapy cure the great majority.\n\nWhether the radiotherapy can be dropped in patients whose PET is negative has been asked twice, and both answers were the same. HD16 randomised 1,150 patients: among 628 who were PET-negative after two cycles, five-year progression-free survival was 93.4 per cent with combined-modality treatment against 86.1 per cent with ABVD alone (difference 7.3 percentage points, hazard ratio 1.78), with five-year overall survival of 98.1 and 98.4 per cent. RAPID randomised patients whose PET was negative after three cycles and found three-year progression-free survival of 94.6 per cent with radiotherapy against 90.8 per cent without, with no difference in overall survival and non-inferiority not formally shown.\n\nSo omitting radiotherapy costs a few percentage points of disease control and costs nothing in survival, while avoiding a field over the heart, breasts, thyroid and lungs in a person who will live another fifty years. It is a genuine choice and it is made differently by different patients and different countries. A Deauville score of 4 on the interim PET predicts a much higher risk of failure than a score of 3, and those patients keep the radiotherapy.","refs":["paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010","paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015","abvd-beacopp","doxorubicin","bleomycin","vinblastine","dacarbazine","imrt-igrt","deauville","fdg-pet","lymphoma-tx-radiotherapy","lymphoma-tx-hodgkin-late-effects"],"guideline":{"nccn":"Category 1","version":"NCCN Hodgkin Lymphoma; ESMO; HD10, HD16, RAPID","url":"https://doi.org/10.1200/JCO.19.00964"}},{"setting":"Early unfavourable Hodgkin lymphoma: more chemotherapy, and PET-guided intensification","approach":"Early-stage disease with risk factors (a large mediastinal mass, extranodal involvement, a raised erythrocyte sedimentation rate, three or four or more nodal areas, or age 50 or over depending on the criteria used) is treated with four cycles of chemotherapy and involved-site radiotherapy at 30 Gy, or with more intensive chemotherapy in place of some of it.\n\nEORTC/LYSA/FIL H10 randomised 1,950 patients and settled the PET-adapted question in both directions. In the 18.8 per cent whose PET after two cycles of ABVD was positive, switching to two cycles of escalated BEACOPP with involved-node radiotherapy raised five-year progression-free survival from 77.4 to 90.6 per cent (hazard ratio 0.42). In PET-negative patients, non-inferiority of ABVD alone could not be demonstrated in either the favourable group (99.0 against 87.1 per cent for combined-modality treatment) or the unfavourable group (92.1 against 89.6 per cent), so omitting radiotherapy again costs disease control.\n\nBrentuximab vedotin with AVD is an option for unfavourable early-stage disease in some guidelines, and AHOD2131, an international trial in patients aged 5 to 60 with stage I to II disease, is testing response-adapted brentuximab vedotin with nivolumab against standard therapy with or without radiation. That trial is the one most likely to change this row next.","refs":["ahod2131","abvd-beacopp","brentuximab-vedotin","nivolumab","doxorubicin","bleomycin","vinblastine","dacarbazine","etoposide","cyclophosphamide","procarbazine","imrt-igrt","fdg-pet","deauville","lymphoma-tx-radiotherapy"],"guideline":{"nccn":"Category 1","version":"NCCN Hodgkin Lymphoma; ESMO; EORTC H10","url":"https://doi.org/10.1200/JCO.2016.68.6394"}},{"setting":"Children, adolescents and young adults with early-stage Hodgkin lymphoma","approach":"Paediatric protocols differ from adult ones in two ways that matter: they use response-adapted designs to remove radiotherapy from as many children as possible, and they avoid or limit the agents with the worst late effects in a growing body, particularly alkylating agents and chest radiotherapy.\n\nChildren's Oncology Group and EuroNet protocols give a short course of multi-agent chemotherapy, assess response with PET after two cycles, and give involved-site radiotherapy only to sites that have not responded adequately. The aim is to cure more than 95 per cent of children with the smallest cumulative dose of anthracycline, alkylator and radiation they can be cured with.\n\nAHOD1331 showed the direction of travel in high-risk paediatric disease: replacing bleomycin with brentuximab vedotin gave three-year event-free survival of 92.1 per cent against 82.5 per cent (hazard ratio 0.41), with three-year overall survival of 99.3 against 98.5 per cent, similar toxicity and a similar proportion receiving radiotherapy (53.4 against 56.8 per cent). AHOD2131 is now testing brentuximab vedotin with nivolumab against standard therapy in early-stage disease across the ages of 5 to 60, which is unusual and deliberate: adolescents and young adults have historically fallen between paediatric and adult trials and done worse for it.\n\nGrowth, fertility, thyroid function, cardiac function and psychological support are part of the treatment plan from the first appointment, not the end of it.","refs":["paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022","ahod2131","brentuximab-vedotin","nivolumab","bleomycin","doxorubicin","imrt-igrt","fdg-pet","lymphoma-tx-fertility-preservation","lymphoma-tx-hodgkin-late-effects"],"guideline":{"version":"NCI PDQ childhood Hodgkin lymphoma; COG and EuroNet protocols; AHOD1331","url":"https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq"}}],"stateOfArt":["Cure rates above 90 percent make treatment reduction, not intensification, the aim.","Interim PET lets many patients avoid radiotherapy altogether.","Brentuximab vedotin and PD-1 antibodies are entering early-stage trials to replace parts of chemotherapy."],"history":[{"year":1832,"title":"Thomas Hodgkin describes the disease","refs":["reed-sternberg-cell"]},{"year":1962,"title":"Kaplan's extended-field radiotherapy cures early-stage disease at Stanford","refs":["imrt-igrt"]},{"year":1975,"title":"Bonadonna introduces ABVD in Milan","refs":["abvd-beacopp","doxorubicin"]},{"year":2010,"title":"GHSG HD10: two ABVD and 20 Gy suffice for early favourable disease","refs":["abvd-beacopp","imrt-igrt"]},{"year":2015,"title":"RAPID: PET-negative patients can omit radiotherapy at a small cost in relapse","refs":["pet-adapted-therapy","deauville-score"]},{"year":2021,"title":"HD17: radiotherapy omitted in PET-negative early unfavourable disease","refs":["pet-adapted-therapy"]},{"year":2022,"title":"AHOD2131 opens: brentuximab vedotin and nivolumab in early-stage high-risk disease from age 5","refs":["ahod2131","brentuximab-vedotin","nivolumab"]}],"pipeline":["ahod2131","nct03407144","pet-adapted-therapy","brentuximab-vedotin","nivolumab","ctdna-lymphoma-monitoring"],"openProblems":["Radiotherapy omission trades a few percent more relapses against late harms that take decades to appear.","Bleomycin lung toxicity and doxorubicin cardiotoxicity persist even in short regimens.","Whether PD-1 antibodies can replace chemotherapy in early disease is untested.","Older patients with early disease tolerate ABVD poorly and have no dedicated standard."],"parent":"hodgkin-lymphoma"},"route":"/cancers/early-stage-classical-hodgkin-lymphoma/","neighbours":{"cancer":[{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"nodular-lymphocyte-predominant-hodgkin-lymphoma","kind":"cancer","name":"Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)","route":"/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/"},{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}],"idea":[{"id":"lymphoma-ev-radiotherapy-free-early-hodgkin","kind":"idea","name":"A radiotherapy-free cure for early Hodgkin lymphoma that actually holds","route":"/ideas/lymphoma-ev-radiotherapy-free-early-hodgkin/"},{"id":"lymphoma-ev-late-effects-of-the-treatments-given-now","kind":"idea","name":"Measure the late effects of the treatments being given now, not the ones given in 1975","route":"/ideas/lymphoma-ev-late-effects-of-the-treatments-given-now/"},{"id":"lymphoma-ev-ctdna-instead-of-the-interim-scan","kind":"idea","name":"Use circulating tumour DNA instead of the interim scan to decide what happens next","route":"/ideas/lymphoma-ev-ctdna-instead-of-the-interim-scan/"}],"technology":[{"id":"cardio-oncology","kind":"technology","name":"Cardio-oncology","route":"/technologies/cardio-oncology/"},{"id":"cbt-fatigue-distress","kind":"technology","name":"Cognitive behavioural therapy for fatigue and distress","route":"/technologies/cbt-fatigue-distress/"},{"id":"ctdna-lymphoma-monitoring","kind":"technology","name":"ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)","route":"/technologies/ctdna-lymphoma-monitoring/"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/"},{"id":"exercise-during-chemotherapy","kind":"technology","name":"Exercise during chemotherapy and radiotherapy","route":"/technologies/exercise-during-chemotherapy/"},{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/"},{"id":"financial-navigation","kind":"technology","name":"Financial toxicity and financial navigation","route":"/technologies/financial-navigation/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"mammography","kind":"technology","name":"Mammography & tomosynthesis","route":"/technologies/mammography/"},{"id":"multidisciplinary-tumour-board","kind":"technology","name":"Multidisciplinary tumour boards","route":"/technologies/multidisciplinary-tumour-board/"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/"},{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/"},{"id":"peer-support-groups","kind":"technology","name":"Peer support and support groups","route":"/technologies/peer-support-groups/"},{"id":"pet-adapted-therapy","kind":"technology","name":"PET-adapted (response-adapted) therapy","route":"/technologies/pet-adapted-therapy/"},{"id":"prehabilitation","kind":"technology","name":"Prehabilitation before cancer surgery","route":"/technologies/prehabilitation/"},{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/"},{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/"}],"target":[{"id":"cd30","kind":"target","name":"CD30","route":"/targets/cd30/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"bleomycin","kind":"drug","name":"Bleomycin","route":"/drugs/bleomycin/"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"dacarbazine","kind":"drug","name":"Dacarbazine","route":"/drugs/dacarbazine/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"procarbazine","kind":"drug","name":"Procarbazine","route":"/drugs/procarbazine/"},{"id":"vinblastine","kind":"drug","name":"Vinblastine","route":"/drugs/vinblastine/"}],"term":[{"id":"lymphoma-decision-trial","kind":"term","name":"A clinical trial or standard treatment in lymphoma","route":"/terms/lymphoma-decision-trial/"},{"id":"abvd-beacopp","kind":"term","name":"ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)","route":"/terms/abvd-beacopp/"},{"id":"lymphoma-living-hodgkin-survivorship-screening","kind":"term","name":"After Hodgkin lymphoma: the late effects, and the screening that follows them","route":"/terms/lymphoma-living-hodgkin-survivorship-screening/"},{"id":"lymphoma-tx-uk-versus-us","kind":"term","name":"British and American lymphoma practice: where they differ, and why","route":"/terms/lymphoma-tx-uk-versus-us/"},{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/"},{"id":"cardiotoxicity","kind":"term","name":"Cardiotoxicity (LVEF decline, cardiomyopathy)","route":"/terms/cardiotoxicity/"},{"id":"central-venous-access","kind":"term","name":"Central venous access (port, PICC line)","route":"/terms/central-venous-access/"},{"id":"deauville-score","kind":"term","name":"Deauville five-point scale","route":"/terms/deauville-score/"},{"id":"deauville","kind":"term","name":"Deauville score and PET-adapted therapy","route":"/terms/deauville/"},{"id":"lymphoma-living-fatigue","kind":"term","name":"Fatigue after lymphoma treatment, and why it is a symptom to report","route":"/terms/lymphoma-living-fatigue/"},{"id":"febrile-neutropenia","kind":"term","name":"Febrile neutropenia","route":"/terms/febrile-neutropenia/"},{"id":"lymphoma-tx-fertility-preservation","kind":"term","name":"Fertility before lymphoma treatment: what to ask for, and when","route":"/terms/lymphoma-tx-fertility-preservation/"},{"id":"lymphoma-decision-fertility-timing","kind":"term","name":"Fertility preservation before lymphoma treatment: a decision with a deadline in days","route":"/terms/lymphoma-decision-fertility-timing/"},{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/"},{"id":"hypogammaglobulinaemia","kind":"term","name":"Hypogammaglobulinaemia and infection risk after B-cell therapies","route":"/terms/hypogammaglobulinaemia/"},{"id":"late-effects","kind":"term","name":"Late effects and survivorship toxicity","route":"/terms/late-effects/"},{"id":"lymphoma-tx-hodgkin-late-effects","kind":"term","name":"Late effects of Hodgkin lymphoma treatment, and the follow-up that answers them","route":"/terms/lymphoma-tx-hodgkin-late-effects/"},{"id":"lugano-classification","kind":"term","name":"Lugano classification / Ann Arbor staging","route":"/terms/lugano-classification/"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/"},{"id":"performance-status","kind":"term","name":"Performance status (ECOG, Karnofsky)","route":"/terms/performance-status/"},{"id":"quality-of-life","kind":"term","name":"Quality of life","route":"/terms/quality-of-life/"},{"id":"lymphoma-tx-radiotherapy","kind":"term","name":"Radiotherapy in lymphoma: involved-site fields, 24 Gy, 4 Gy and total skin electron therapy","route":"/terms/lymphoma-tx-radiotherapy/"},{"id":"reed-sternberg-cell","kind":"term","name":"Reed-Sternberg cell","route":"/terms/reed-sternberg-cell/"},{"id":"secondary-malignancy","kind":"term","name":"Secondary malignancy (therapy-related cancer)","route":"/terms/secondary-malignancy/"},{"id":"lymphoma-tx-transplant-role","kind":"term","name":"Stem cell transplant in lymphoma: what it is still for","route":"/terms/lymphoma-tx-transplant-role/"},{"id":"lymphoma-tx-regimen-alphabet","kind":"term","name":"The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest","route":"/terms/lymphoma-tx-regimen-alphabet/"},{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/"}],"trial":[{"id":"ahod2131","kind":"trial","name":"AHOD2131 (COG / NCTN)","route":"/trials/ahod2131/"},{"id":"eortc-h10","kind":"trial","name":"EORTC/LYSA/FIL H10","route":"/trials/eortc-h10/"},{"id":"hd10","kind":"trial","name":"GHSG HD10","route":"/trials/hd10/"},{"id":"hd16","kind":"trial","name":"GHSG HD16","route":"/trials/hd16/"},{"id":"radar-hodgkin","kind":"trial","name":"RADAR","route":"/trials/radar-hodgkin/"},{"id":"nct03407144","kind":"trial","name":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","route":"/trials/nct03407144/"}],"paper":[{"id":"paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022","kind":"paper","name":"AHOD1331: brentuximab vedotin with chemotherapy in paediatric high-risk Hodgkin lymphoma","route":"/key-papers/paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022/"},{"id":"paper-travis-breast-cancer-after-hodgkin-radiotherapy-jama-2003","kind":"paper","name":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","route":"/key-papers/paper-travis-breast-cancer-after-hodgkin-radiotherapy-jama-2003/"},{"id":"paper-van-nimwegen-cardiovascular-disease-after-hodgkin-jama-intern-med-2015","kind":"paper","name":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","route":"/key-papers/paper-van-nimwegen-cardiovascular-disease-after-hodgkin-jama-intern-med-2015/"},{"id":"paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017","kind":"paper","name":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial","route":"/key-papers/paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017/"},{"id":"paper-echelon-1-brentuximab-avd-nejm-2018","kind":"paper","name":"ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma","route":"/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/"},{"id":"paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010","kind":"paper","name":"GHSG HD10: reduced treatment intensity in early-stage favourable Hodgkin lymphoma","route":"/key-papers/paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010/"},{"id":"paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019","kind":"paper","name":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","route":"/key-papers/paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019/"},{"id":"paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015","kind":"paper","name":"RAPID: PET-directed therapy for early-stage Hodgkin lymphoma","route":"/key-papers/paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015/"},{"id":"paper-schaapveld-second-cancer-risk-40-years-hodgkin-nejm-2015","kind":"paper","name":"Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma","route":"/key-papers/paper-schaapveld-second-cancer-risk-40-years-hodgkin-nejm-2015/"}],"company":[{"id":"childrens-oncology-group","kind":"company","name":"Children's Oncology Group (COG)","route":"/companies/childrens-oncology-group/"}]}}